Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations~* Body Mass Index (BMI) of 18 to 32 kg/m², inclusive~* Ages 18 to 55, inclusive~Exclusion Criteria:~* Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population~* Major surgical procedure within 4 weeks prior to randomization~* Positive serology test for HIV, HBV or HCV~* Clinically significant history or presence of any of the following conditions: heart, liver, or kidney disease, neurologic or psychiatric disease~* History of gastrointestinal disease within the past 3 months~* Any clinically significant medical condition that could potentially affect your participation in the study and/or personal well-being, as judged by the investigator~* Donated blood or blood products to a blood bank, blood transfusion or participated in a clinical study (except a screening visit) requiring withdrawal of blood within 4 weeks prior to randomization~* Unable to tolerate oral and/or intravenous (IV) medications~* Unable to tolerate the puncturing of veins for drawing of blood~* Known allergy or hypersensitivity to any component of the study medication~* History of any significant drug allergies (such as anaphylaxis or hepatotoxicity)~* Used any prescription drugs or over the counter products to control acid (for example, Prevacid, Mylanta or Rolaids) within 4 weeks prior to randomization~* Used any other drugs including over the counter medications and herbal preparations within 1 week prior to randomization~* Taken any investigational drug or placebo (inactive drug) within 4 weeks prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 5 mg saxagliptin + 2 Glucophage XR 500 mg tablet (Type: EXPERIMENTAL): None
- FDC tablet (5 mg saxa + 1000 mg metformin XR) (single dose) (Type: EXPERIMENTAL): under fed state, single dose
- FDC tablet (5 mg saxa + 1000 mg metformin XR) (4 days) (Type: EXPERIMENTAL): under fed state, 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).